LENZ Therapeutics to Present at Upcoming Investor Conferences
LENZ Therapeutics, Inc. (LENZ)
Company Research
Source: GlobeNewswire
SAN DIEGO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, today announced that company management will participate in the following upcoming investor conferences: TD Cowen 46th Annual Health Care ConferenceDate: March 2, 2026Location: Boston, MAFormat: Fireside chat at 9:50am ET (live audio webcast) and 1x1 investor meetings Leerink Partners 2026 Global Healthcare Conference Date: March 10, 2026Location: Miami, FLFormat: Fireside chat at 10:00am ET (live audio webcast) and 1x1 investor meetings Live audio webcasts will also be available on the LENZ Therapeutics website at www.LENZ-tx.com in the Investors & Media section. A replay of the webcasts will be available on the Company’s website for 12 months following the eve
Show less
Read more
Impact Snapshot
Event Time:
LENZ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LENZ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LENZ alerts
High impacting LENZ Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
LENZ
News
- LENZ Therapeutics, Inc. Investigated by the Portnoy Law FirmGlobeNewswire
- LENZ Therapeutics (LENZ) had its price target lowered by HC Wainwright from $56.00 to $48.00. They now have a "buy" rating on the stock.MarketBeat
- LENZ Therapeutics Announces Submission of Marketing Authorization Application to the Medicines and Healthcare products Regulatory Agency for VIZZ® for the Treatment of Presbyopia in the United KingdomGlobeNewswire
- LENZ Therapeutics: Speculative But Strong Buy [Seeking Alpha]Seeking Alpha
- The Consensus EPS Estimates For LENZ Therapeutics, Inc. (NASDAQ:LENZ) Just Fell Dramatically [Yahoo! Finance]Yahoo! Finance
LENZ
Earnings
- 3/24/26 - Miss
LENZ
Sec Filings
- 4/28/26 - Form ARS
- 4/28/26 - Form DEFA14A
- 4/28/26 - Form DEF
- LENZ's page on the SEC website